Terminated PHASE3 INTERVENTIONAL 2-arm NCT00571753

Isoniazid Dose Adjustment According to NAT2 Genotype (IDANAT2)

A Double-blind, Multicentre, Parallel Group, Randomised, Controlled Trial to Evaluate the Possible Benefit of Isoniazid Dose Adjustment According to the Genotype for NAT2 (Arylamine N-acetyltransferase Type 2) in Patients With Pulmonary Tuberculosis

Sponsor: University of Cologne

Conditions Pulmonary Tuberculosis

Interventions isoniazid

Updated 2 times since 2024 Last updated: Feb 25, 2011 Started: Jun 30, 2008 Primary completion: Dec 31, 2011 Completion: Feb 29, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Enrolling participants has halted prematurely due to a low recruitment rate.

Other terminated trials from University of Cologne

See all terminations from University of Cologne

A PHASE3 clinical study on Pulmonary Tuberculosis, this trial is terminated or withdrawn. The trial is conducted by University of Cologne and has accumulated 2 data snapshots since 2008. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Cologne

Data source: University of Cologne

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bad Berka, Germany , Bad Lippspringe, Germany , Berlin, Germany , Chodzież, Poland , Cologne, Germany , Frankfurt am Main, Germany , Heidelberg, Germany , Immenhausen, Germany , Poznan, Poland , Rotenburg (Wümme), Germany and 2 more locations